Immunotherapy

Papers
(The H4-Index of Immunotherapy is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Identifying risk factors and biomarkers for severe CIP in lung cancer patients– a retrospective case series study71
Atezolizumab and Bevacizumab prior to liver transplantation in hepatic angiosarcoma mimicking hepatocellular carcinoma65
Imaging of brain metastases treated with immune checkpoint inhibitors52
Chimeric Antigen Receptor Macrophage for Glioblastoma Immunotherapy: The Way Forward40
Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer Without Tumor Pd-L1 Expression in Asia40
Cost–Effectiveness Analysis of Serplulimab as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma35
CT-P13 Subcutaneous Infliximab in Gastroenterology and Rheumatology31
An Update on the Adalimumab Biosimilar Landscape Following Approval of the First High-Concentration Biosimilar30
Alemtuzumab-Induced Red Cell Aplasia And Other Immune Cytopenias: Not So €˜Pure’29
Real-world Study of Hepatic Artery Infusion Chemotherapy Combined With Anti-PD-1 Immunotherapy and Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma27
Real-World Outcomes with Immuno-Oncology Therapies in Advanced Melanoma: Final Results of the OPTIMIzE Registry Study26
Pembrolizumab in patients from China with microsatellite instability-high/mismatch repair deficient tumors: KEYNOTE-15825
Safety and Effectiveness of the 300 IR Sublingual House Dust Mite Allergen Immunotherapy Tablet: 2-Year Interim Analysis of a Specified Drug-Use Survey24
Subcutaneous Immunoglobulin Use in Immunoglobulin-Naive Patients with Primary Immunodeficiency: A Systematic Review23
Pd-1, Pd-L1, Ido, Cd70 and Microsatellite Instability as Potential Targets to Prevent Immune Evasion in Sarcomas22
Targeting PD-1/PD-L1 in Biliary Tract Cancer: Role and Available Data20
Postvaccination immune-mediated hepatitis: what do we really know?19
Treatment and Overall Survival Among Anti-PD-1-Exposed Advanced Melanoma Patients with Evidence of Disease Progression18
0.153559923172